Clinical application of autologous in vivo tissue engineered vascular grafts in surgical management of congenital heart diseases

2022 Fiscal Year Final Research Report

• Project/Area Number: 20K09131
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 55030:Cardiovascular surgery-related
• Research Institution: Kyoto Prefectural University of Medicine
• Principal Investigator: Maeda Yoshinobu 京都府立医科大学, 医学(系)研究科(研究院), 助教 (20438203)
• Co-Investigator(Kenkyū-buntansha): 山岸 正明 京都府立医科大学, 医学(系)研究科(研究院), 特任教授 (40182422)
• Project Period (FY): 2020-04-01 – 2023-03-31
• Keywords: 生体内組織工学 / 先天性心疾患 / 代用心膜 / 自家移植 / 自己結合組織

Outline of Final Research Achievements

The subjects were 10 cases. The total number of implanted silicon molds was 33, with a median of 2 (2-4) per time.
After a median waiting period of 268 days for implantation, a good autologous tissue engineered vascular grafts was formed around the harvested mold in all cases, and it can be used as a material for pulmonary augmentation without problems. No adverse events (hemorrhage, aneurysm degeneration, infection) were observed during the follow-up period after pulmonary artery augmentation using autologous tissue engineered vascular grafts.
The suture retention strength and burst pressure of the collected autologous tissue engineered vascular grafts were equal to or higher than those of other blood vessels of the same species (human).

Free Research Field

先天性心疾患の外科治療

Academic Significance and Societal Importance of the Research Achievements

先天性心疾患の外科治療はその複雑な疾患特性より複数回の手術を必要とすることが多い一方で、成長発育の観点からできる限り自己組織による形態修復をも必要とされる。本研究で示された自己結合組織膜の有用性は自己心膜や人工血管の代用素材として非常に有効であり、今後の先天性心疾患治療において福音となるものである。